Phase I/II Experience of Pixantrone CHOP-Variant (CPOP) Produces Responses in 70 Percent of Relapsed Aggressive Non-Hodgkin's Lymphoma Patients Who Previously Failed CHOP Chemotherapy.

PR Newswire Europe, December, 2004

SAN DIEGO, December 6 /PRNewswire/ --

- Complete Responses Seen in 47 Percent of Patients

Preliminary results of a phase II study of a variant of the CHOP chemotherapy regimen which replaces doxorubicin with pixantrone in patients with relapsed aggressive non-Hodgkin's lymphoma (NHL) were presented at the 46th Annual Meeting of the American Society of Hematology (ASH). The phase II study of the pixantrone combination regimen, known as CPOP, produced impressive response rates including complete responses in 41 percent of the patients who had previously failed the standard CHOP chemotherapy and at least one additional multi-chemotherapy regimen. The treatment was effective and well tolerated. No patients experienced clinically significant cardiac...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.